ImmuCell Corporation (NASDAQ: ICCC), a Portland, Maine-based animal health biologics company focused on dairy and beef cattle, is thinly followed by Wall Street. Market data providers show a consensus rating rather than a meaningful price target, and the only named coverage is a long-standing analyst with no current target figure. Because no usable analyst price target exists, this article uses the fallback approach: a price objective that is actually discussed in public market commentary.
That objective comes from independent special-situation research, which notes that after excluding one-time charges, ImmuCell's fiscal 2025 adjusted EBITDA was roughly $5.8 million. Applying a 20x multiple produces a value near $116 million, or approximately $12.80 per share, often rounded to about $13. This is a valuation-based discussion point, not a guarantee or an official consensus, and it sits above the stock's 52-week high of $12.10.
ImmuCell's stock closed near $10.26 in late October 2026, giving the company a market capitalization of roughly $93 million. The 52-week range runs from $4.52 to $12.10, and the shares have risen more than 60% over the past year. Reaching $13 from $10.26 implies a gain of about 27%, which is a substantial move for a micro-cap with average daily volume in the low thousands of shares.
The path toward that level would likely depend on continued execution in the core First Defense calf-scours franchise. ImmuCell reported record first-quarter 2026 product sales of $10.4 million and preliminary third-quarter sales of $8.0 million, up 46% year over year, with nine-month sales up about 28%. Management's stated plan to expand manufacturing capacity to more than triple current output by 2027 is central to the growth narrative, though near-term gross margin has been pressured by lower manufacturing yields and product-mix shifts.
The most durable reference points are the 52-week high of $12.10 and the 52-week low of $4.52. Because the $13 target sits just above the 52-week high, that $12.10 level functions as a notable resistance zone and potential breakout area. The stock crossed back above its 200-day moving average earlier in 2026 after a strong advance, reflecting a repaired long-term trend, but the $10.00 round-number level and the prior trading range near $8.50 to $9.50 are nearby support areas to monitor on any pullback.
The $13 figure is a valuation discussion point rather than a dated analyst target, so it carries no formal time horizon. In practice, valuation-based objectives of this kind are usually assessed over roughly a twelve-month window, but no specific period is implied. Investors should watch the next quarterly report, scheduled for mid-November 2026, along with guidance on gross margin, manufacturing yields, the pace of capacity-expansion spending, and any recovery in international sales. Because analyst coverage is minimal, company-issued updates on sales and margin trajectory will likely matter more than consensus revisions.
For traders tracking names like ICCC, Tickeron's AI Daily Buy/Sell Signals offer a complementary, data-driven view. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual review alone. Traders looking for an automated edge in a fast-moving micro-cap environment can explore these AI-generated signals as part of a broader research process.
Can ICCC reach $13? The target rests on a publicly discussed valuation of roughly $12.80 per share, derived from a 20x multiple of adjusted EBITDA, rather than on sell-side analyst coverage, which is effectively absent. Reaching it would require about a 27% advance from the current price near $10.26. The clearest supports are accelerating product sales, rising U.S. market share, and a capacity-expansion program that could lift output and, eventually, margins. The principal obstacles are thin and volatile earnings, recent gross-margin compression, weak international sales, and a premium valuation that leaves little cushion for setbacks. Investors should watch the upcoming earnings report, margin trends, and capacity execution, and should treat the $13 figure as a discussion point rather than a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ICCC has been loosely correlated with NKTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ICCC jumps, then NKTX could also see price increases.
| Ticker / NAME | Correlation To ICCC | 1D Price Change % | ||
|---|---|---|---|---|
| ICCC | 100% | +0.39% | ||
| NKTX - ICCC | 43% Loosely correlated | -15.09% | ||
| JANX - ICCC | 27% Poorly correlated | -5.64% | ||
| BOLT - ICCC | 26% Poorly correlated | -2.02% | ||
| NERV - ICCC | 24% Poorly correlated | -5.32% | ||
| IMMP - ICCC | 23% Poorly correlated | -8.95% | ||
More | ||||